Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.59 |
| ▸ | MMP3 | P08254 | 9/20 | 0.59 |
| ▸ | MMP1 | P03956 | 8/20 | 0.59 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 5/20 | 0.56 |
| ▸ | MMP8 | P22894 | 3/20 | 0.56 |
| ▸ | MMP14 | P50281 | 3/20 | 0.52 |
| ▸ | FCER2 | P06734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763651 | 1.00 | MMP2 (0.59) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL7763746 | 0.91 | MMP2 (0.49) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL7763742 | 0.91 | MMP2 (0.49) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL6270672 | 0.91 | MMP2 (0.65) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL6270662 | 0.91 | MMP2 (0.65) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL6270502 | 0.86 | MMP12 (0.64) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL6270497 | 0.86 | MMP12 (0.64) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL7765152 | 0.85 | MMP2 (0.55) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL8321331 | 0.85 | MMP2 (0.55) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL6279998 | 0.83 | MMP2 (0.53) | MMP2MMP3MMP1MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |